Posted: December 29th, 2012 | Author: M.Aaron Silverman | Filed under: Applied Science, Cankler Science News, Chemically Engineered, Engineered Life, Health, Medicated | Tags: Breast Cancer, Cancer, Cancer Research, ELF5 Protien, Garvin Institute, Protein-to-protein Interaction, RNA, Therapeutic Options | Comments Off on Garvin Institute Discover Critical Breast Cancer Protien
Australian researchers have discovered a key factor explaining the lack of effectiveness of some breast cancer treatments. Associate Professor Chris Ormandy from Sydney’s Garvan Institute says a protein he has been studying for a decade plays a critical role in the development of breast cancer.
The researchers have shown how a ‘transcription factor’ causes breast cancer to develop an aggressive subtype that lacks sensitivity to oestrogen and does not respond to anti-oestrogen therapies such as Tamoxifen and aromatase inhibitors.
Transcription factors are molecules that switch genes on or off. In this case, the transcription factor known as ‘ELF5’ inhibits sensitivity to oestrogen very early in the life of a breast cancer cell :: Read the full article »»»»
Posted: October 25th, 2012 | Author: Michael Courtenay | Filed under: Cankler Science News, Medicated | Tags: Garvin Institute, International Cancer Genome Consortium, Mutated Genes, Pancreatic Cancer, Personalised Medicine | Comments Off on Pancreatic Cancer Genes Identified by Garvin Researchers
Australian scientists have identified a set of mutated genes responsible for pancreatic cancer – one of the most lethal forms of cancer, with very few treatment options – a finding that could lead to early detection and better treatment of the disease.
Pancreatic cancer is highly aggressive and has the highest death rate of the major cancerous diseases, with patients normally dying within months of diagnosis. The researchers say that the genetic sequencing of the DNA of tumours and patients will go into global database known as the International Cancer Genome Consortium – ICGC – which will assist researchers from around the globe in comparing the success and failure of drug treatments and other therapies.
Professor Andrew Biankin from the Kinghorn Cancer Centre at Sydney’s Garvin Institute and co-author of a study appearing in the scientific journal Nature, says treating pancreatic cancer is a race against time :: Read the full article »»»»